Annotation and Specificity of Existing Genome-Wide Small Interfering RNA Libraries

2013 ◽  
Vol 23 (1) ◽  
pp. 71-80 ◽  
Author(s):  
Karol Kozak
2022 ◽  
Vol 119 (3) ◽  
pp. e2105171119
Author(s):  
Raghuvaran Shanmugam ◽  
Mert Burak Ozturk ◽  
Joo-Leng Low ◽  
Semih Can Akincilar ◽  
Joelle Yi Heng Chua ◽  
...  

Cancer-specific hTERT promoter mutations reported in 19% of cancers result in enhanced telomerase activity. Understanding the distinctions between transcriptional regulation of wild-type (WT) and mutant (Mut) hTERT promoters may open up avenues for development of inhibitors which specially block hTERT expression in cancer cells. To comprehensively identify physiological regulators of WT- or Mut-hTERT promoters, we generated several isogenic reporter cells driven by endogenous hTERT loci. Genome-wide CRISPR-Cas9 and small interfering RNA screens using these isogenic reporter lines identified specific regulators of Mut-hTERT promoters. We validate and characterize one of these hits, namely, MED12, a kinase subunit of mediator complex. We demonstrate that MED12 specifically drives expression of hTERT from the Mut-hTERT promoter by mediating long-range chromatin interaction between the proximal Mut-hTERT promoter and T-INT1 distal regulatory region 260 kb upstream. Several hits identified in our screens could serve as potential therapeutic targets, inhibition of which may specifically block Mut-hTERT promoter driven telomerase reactivation in cancers.


2014 ◽  
Vol 88 (15) ◽  
pp. 8565-8578 ◽  
Author(s):  
R. Meier ◽  
A. Franceschini ◽  
P. Horvath ◽  
M. Tetard ◽  
R. Mancini ◽  
...  

2013 ◽  
Vol 59 (3) ◽  
pp. 367-376 ◽  
Author(s):  
Jacob T. Shreve ◽  
Richard H. Shukle ◽  
Subhashree Subramanyam ◽  
Alisha J. Johnson ◽  
Brandon J. Schemerhorn ◽  
...  

2005 ◽  
Vol 79 (22) ◽  
pp. 14392-14403 ◽  
Author(s):  
Yong Guo ◽  
Hongyan Guo ◽  
Liang Zhang ◽  
Hongying Xie ◽  
Xin Zhao ◽  
...  

ABSTRACT Hepatitis B virus (HBV) causes acute and chronic hepatitis and hepatocellular carcinoma. Small interfering RNA (siRNA) and lamivudine have been shown to have anti-HBV effects through different mechanisms. However, assessment of the genome-wide effects of siRNA and lamivudine on HBV-producing cell lines has not been reported, which may provide a clue to interrogate the HBV-cell interaction and to evaluate the siRNA's side effect as a potential drug. In the present study, we designed seven siRNAs based on the conserved HBV sequences and tested their effects on the expression of HBV genes following sorting of siRNA-positive cells. Among these seven siRNAs, siRNA-1 and siRNA-7 were found to effectively suppress HBV gene expression. We further addressed the global gene expression changes in stable HBV-producing cells induced by siRNA-1 and siRNA-7 by use of human genome-wide oligonucleotide microarrays. Data from the gene expression profiling indicated that siRNA-1 and siRNA-7 altered the expression of 54 and 499 genes, respectively, in HepG2.2.15 cells, which revealed that different siRNAs had various patterns of gene expression profiles and suggested a complicated influence of siRNAs on host cells. We further observed that 18 of these genes were suppressed by both siRNA-1 and siRNA-7. Interestingly, seven of these genes were originally activated by HBV, which suggested that these seven genes might be involved in the HBV-host cell interaction. Finally, we have compared the effects of siRNA and lamivudine on HBV and host cells, which revealed that siRNA is more effective at inhibiting HBV expression at the mRNA and protein level in vitro, and the gene expression profile of HepG2.2.15 cells treated by lamivudine is totally different from that seen with siRNA.


Sign in / Sign up

Export Citation Format

Share Document